Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BalchemBCPC -0.23%94 3-Year EBITDA Growth Rate is 8.90% as of Mar. 2026, which is 37% below its 10-year median of 14.20. GuruFocus rates BCPC with a GF Score™ of 94/100 and a GF Value™ of $177.97 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,409 Chemicals companies, Balchem ranks better than 65.08% on this metric.
During the past 12 months, Balchem's average EBITDA Per Share Growth Rate was 10.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 8.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 9.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 6.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Balchem was 45.20% per year. The lowest was -2.30% per year. And the median was 14.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Balchem 3-Year EBITDA Growth Rate Related Terms
BCPC vs PRM, SXT, CBT: 3-Year EBITDA Growth Rate Comparison
For the Specialty Chemicals subindustry, Balchem's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Balchem 3-Year EBITDA Growth Rate vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Balchem's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Balchem's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 8.90% mean?
Balchem (BCPC) has a 3-Year EBITDA Growth Rate of 8.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Balchem and its competitors. This is 37% below median its historical median of 14.20. According to the industry distribution chart, Balchem ranks #492 out of 1409 companies in the Chemicals industry, placing it in the top 34.9%.
Is Balchem's 3-Year EBITDA Growth Rate too high?
Balchem's current 3-Year EBITDA Growth Rate of 8.90% is 37% below median its 10-year median of 14.20. The Chemicals industry median 3-Year EBITDA Growth Rate is 0.90. Balchem's value of 8.90% is 888.9% above this industry median. Based on the distribution chart, Balchem ranks #492 out of 1409 companies in the Chemicals industry, which is above the industry midpoint. Overall, Balchem has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Balchem's 3-Year EBITDA Growth Rate compare to PRM and SXT?
According to the Chemicals industry distribution chart, Balchem ranks #492 out of 1409 companies for 3-Year EBITDA Growth Rate. This puts Balchem in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 0.90. Balchem's value of 8.90% is 888.9% above this benchmark. While the company's 10-year median is 14.20 vs. the industry median of 0.90, Balchem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Chemicals company?
The median 3-Year EBITDA Growth Rate among Chemicals companies is 0.90, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Balchem's current 3-Year EBITDA Growth Rate of 8.90% is 888.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Balchem and its competitors. For the Chemicals industry, the median 3-Year EBITDA Growth Rate is 0.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Balchem's current 3-Year EBITDA Growth Rate is 8.90%, which is 37% below median its own 10-year median of 14.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balchem stock overvalued right now?
Based on GuruFocus' analysis, Balchem (BCPC) is currently considered Fairly Valued. The stock's GF Value™ is $177.97, compared to a current price of $162.97 — trading 8.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 8.90%, which is 37% below median its 10-year median of 14.20 and 888.9% above the Chemicals industry median of 0.90. Balchem's overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Balchem (BCPC), the current 3-Year EBITDA Growth Rate is 8.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Balchem (BCPC) Overvalued in 2026?
Based on GuruFocus' analysis, Balchem stock appears to be undervalued.
The current stock price of $162.97 is trading 8.4% below its estimated GF Value™ of $177.97.
GuruFocus considers Balchem to be Fairly Valued.
Key valuation signals for BCPC:
3-Year EBITDA Growth Rate: 8.90% (37% below median its 10-year median of 14.20)
GF Value™: $177.97 vs. price of $162.97 (8.4% below fair value)
Industry Position: 888.9% above the Chemicals median (#492 of 1409)
No single metric tells the full story. See the BCPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
94GF Score
Get the complete analysis for BCPC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCPC has been successfully added to your 
